(Total Views: 659)
Posted On: 01/12/2021 11:49:00 PM
Post# of 148905
Quote:
We found a significantly lower frequency of CCR5-Δ32 among the COVID-19 patients (0.10 vs 0.18 in controls; p=0.002, OR=0.48, 95%CI=0.29-0.76).
From https://www.medrxiv.org/content/10.1101/2020....659v1.full
If LL achieves high receptor occupancy rates approaching the effect of CCR5-Δ32, then we may see ~44% success rate in preventing progression from moderate to severe condition in COVID-19 patients.
(1)
(0)Scroll down for more posts ▼
